Inspiron Evo

EVO represents the fourth generation of the Inspiron stent, an advanced evolution designed to offer a state-of-the-art drug-eluting stent. It features a reduced profile, superior navigability and enhanced radial force.

Catalogue

Inspiron Evo - Scitech

Structure & Design

Optimized design

Manufactured from cobalt-chromium (CoCr) with a thin thickness of 75μm, the stent provides an excellent crossing profile and robust radial force. Its hydrophilic delivery system enhances flexibility and supports high balloon burst pressure. The abluminal coating combines PLA and PLGA polymers with an optimized dosage of Sirolimus, creating a moderate drug elution profile that promotes rapid and uniform endothelialization.

The EVO drug-eluting stent features a significantly reduced profile compared to its previous generation, enhancing its ability to cross lesions with exceptional ease.

EVO - Scitech

Improved Navigability

The evolution of the Inspiron stent introduces a design with exceptional navigability, even in the most challenging anatomies, thanks to its significantly reduced profile, hydrophilic delivery system, and innovative balloon fold configuration. Additionally, its optimized design ensures excellent lateral access at bifurcations.

Radial Force

The EVO stent features a newly optimized design that enhances radial force while maintaining its final thickness of 75μm.

Abluminal coating

Layer thickness of 5 μm
Rounded structure designed to minimize the risk of arterial damage
I features “S” connectors that enhance flexibility and navigability

Cobertura abluminal - Polímero 100% biodegradável

Optimized design with slim structures

Optimized design with slim structures
Cobalt Chrome Alloy of 75 μm thickness structure
Exceptional radial force)

Disponível em 48m - Scitech

Revestimento Hidrofílico - Alta pressão de ruptura nominal

Hydrophilic coating
High nominal burst pressure

Design avançado com estruturas finas

Optimized design with slim structures
Cobalt Chrome Alloy of 75 μm thickness structure.
Exceptional radial force

Clinical Studies

The Inspiron stent demonstrates in-stent late luminal loss that is non-inferior to that of Biolimus-eluting stents’, while exhibiting superior strut coverage in OCT (Optical Coherence Tomography) analysis compared to
Biolimus-eluting stents (p<.001) at 9-months²

The Inspiron stent exhibited an impressive strut coverage pattern of over 90% within the first month, achieving 97.21% coverage by the third month³.

The Inspiron stent has demonstrated proven safety and efficacy, characterized by low rates of thrombosis in long-term follow-up studies’-s

Inspiron Real Life I – Novel DES in high-risk patients3
900 days of median follow-up [n=470]*

Destiny Trial:
Safety proven over 5 years

Table of Size and Catalogue Number

Length

Diameter9mm13mm16mm19mm23mm29mm33mm38mm48mm58mm
2.25mm128032128034128035128036128037
2.5mm128040128041128042128043128044128045128046128047
2.75mm128050128051128052128053128054128055128056128057
3.0mm128060128061128062128063128064128065128066128067128068128069
3.5mm128070128071128072128073128074128075128076128077128078128079
4.0mm128080128081128082128083128084128085

Not available in Europe, North America and Asia

R01 – 2025

References

¹Lemos PA, et al. Cardiovasc Ther. 2015 Dec;33(6):367-71. DESTINY Randomized Trial; ²Costa JR Jr, et al. Int J Cardiovasc Imaging. 2017 Feb;33(2):161-

-168. IVUS and OCT results of the DESTINY trial.; ³Silva GBG, et al. J Invasive Cardiol. 2023 May;35(5):E225-E233. Epub 2023 Mar 13. REPAIR Trial.; ⁴Prado
GFA Jr, et al. Rev Port Cardiol (Engl Ed). 2021 Feb;40(2):71-76. Five-year results of the DESTINY randomized trial.; 5Inspiron Real Life I – Novel DES in
high-risk patients (n=470; 900 dias médios de seguimento) – Dados publicados somente até 300 dias de segmento.

R01 – 2025